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Objective: High bone mass (HBM) is associated with an increased prevalence of radiographic 
knee OA (kOA), characterized by osteophytosis. We aimed to determine if progression of 
radiographic kOA, and its sub-phenotypes, is increased in HBM and whether observed 
changes are clinically relevant.  
Design: A cohort with and without HBM (L1 and/or total hip bone mineral density Z-
score>+3.2) had knee radiographs collected at baseline and 8-year follow-up. Sub-
phenotypes were graded using the OARSI atlas. Medial/lateral tibial/femoral osteophyte 
and medial/lateral joint space narrowing (JSN) grades were summed and Δosteophytes, 
ΔJSN derived. Pain, function and stiffness were quantified using the WOMAC questionnaire. 
Associations between HBM status and sub-phenotype progression were determined using 
multivariable linear/poisson regression, adjusting for age, sex, height, baseline sub-
phenotype grade, menopause, education and total body fat mass (TBFM). Generalized 
estimating equations accounted for individual-level clustering. 
Results: 169 individuals had repeated radiographs, providing 330 knee images; 63% had 
HBM, 73% were female, mean(SD) age was 58(12) years. Whilst HBM was not clearly 
associated with  overall Kellgren-Lawrence measured progression (RR=1.55[0.56,4.32]), 
HBM was positively associated with both Δosteophytes and ΔJSN individually (adjusted 
mean differences between individuals with and without HBM 0.45[0.01,0.89] and 
0.15[0.01,0.29], respectively). HBM individuals had higher WOMAC knee pain scores 
(β=7.42[1.17,13.66]), largely explained by adjustment for osteophyte score (58% 
attenuated) rather than JSN (30% attenuated) or TBFM (16% attenuated). The same pattern 




Conclusions: HBM is associated with osteophyte progression, which appears to contribute 





The relationship between bone mineral density (BMD) and osteoarthritis (OA) has been of 
interest for almost 50 years, since the observation that femoral heads removed during 
surgical repair of hip fracture were mostly unaffected by OA, indicating a potential inverse 
association between osteoporosis and OA (1). Since then, several large population-based 
studies assessing the relationship between BMD and prevalent and/or incident radiographic 
knee OA (kOA, usually defined as a Kellgren-Lawrence (KL) grade>2) have suggested that 
higher BMD is a risk factor for both (2-8). Fewer studies have assessed individual 
radiographic sub-phenotypes of kOA (e.g. osteophytes and joint space narrowing [JSN]), 
although in the Framingham population prevalent osteophytosis, rather than JSN, was 
associated with higher BMD (2) and in the Chingford study hip BMD was related to incident 
knee osteophytes (9). 
Evidence for an association between BMD and radiographic kOA progression has been less 
consistent. Zhang et al found evidence for a lower odds of kOA progression with higher BMD 
quartile in the Framingham cohort (6), whereas Hart et al found lower hip BMD in women 
with progressive JSN from the Chingford study (9). An analysis from the Rotterdam study 
suggested that higher lumbar spine BMD (LS-BMD) is associated with an increased odds of 
kOA and osteophyte progression (10); however, this was refuted by analyses from the 
multicentre osteoarthritis study  and the Johnston county osteoarthritis project (JoCo) (11, 
12). Consistent with a protective effect of BMD on risk of kOA progression, strontium 
ranelate, an osteoporosis treatment reported to increase bone formation and decrease 
bone resorption, reduced knee cartilage loss (assessed by JSN) and western Ontario and 




A novel approach to investigate the ‘BMD-progressive kOA’ relationship is to examine a 
population with generalized high BMD, as the causal direction between BMD and kOA can 
be inferred due to the temporal relationship (1). The UK-based High Bone Mass (HBM) study 
is a multi-centred study of individuals with unexplained (i.e. not by disorders known to 
artefactually elevate BMD) generalized high BMD and their unaffected relatives (14). 
Previous analyses have identified an increased odds of prevalent radiographic kOA in 
individuals with HBM, with an increased odds of osteophytes, but not JSN (15). Although 
previous analyses identified increased fat mass in HBM individuals (16) and adiposity as a 
risk factor for kOA (17), BMI adjustment only partly explained the relationship between 
HBM and kOA (15). The prevalence of joint replacement and NSAID use were also higher in 
individuals with HBM, suggestive of increased OA progression (18). We hence aimed to 
establish the relationship between HBM and radiographic kOA progression, particularly 
osteophyte progression. We further aimed to determine whether individuals with HBM 







The High Bone Mass study 
Participants were recruited as part of the UK-based HBM study. Index cases were initially 
identified by screening Dual energy X-ray absorptiometry (DXA) databases for T and/or Z-
scores>+4. All DXA images were inspected by trained clinicians in order to exclude scans 
with artefactual elevation of DXA BMD (e.g. degenerative disease, OA, surgical/malignant 
artefacts). Full details of DXA database screening and participant recruitment have been 
published (14). Index cases passed on invitations to first-degree relatives and 
spouses/partners who underwent the same assessments. Participants who were aged <18, 
pregnant, or unable to give written informed consent were excluded. In first-degree 
relatives, HBM was defined as summed L1 plus TH Z-score>+3.2. HBM in spouses was 
defined as per index cases. In addition to greater BMD, pQCT analyses have identified a 
larger periosteal circumference and evidence of a greater bone volume (19). Recruitment 
ran between 2005-2010. In total, 437 individuals were recruited from the eight centres 
participating in follow-up, of which 274 (63%) had HBM. 254 (58%) alive and consenting 
participants were followed up between 2017-2018; 217 (85%) completed a postal 
questionnaire and 174 (69%) attended for follow-up knee radiographs (Supplementary 
Figure 1).  
Written informed consent was obtained in line with the declaration of Helsinki (20). The 
study was approved by the Bath Multi-centre Research Ethics Committee (REC reference 
05/Q2001/78) and each local NHS REC. Follow-up data collection was approved by the 





DXA scans were performed of the TH and LS at baseline and, after eight years follow-up, of 
the TH, LS and total body (TB) using standard protocols at each assessment centre. 169/174 
(97%) participants re-attended their original assessment centre, limiting measurement error 
due to differential procedures. DXA scans were performed on Hologic scanners in Bath, 
Bristol, Oxford, Sheffield and St George’s and GE Lunar scanners in Cambridge and Hull. 
Known differences in calibration exist between Hologic and Lunar (21, 22). We limited 
systematic bias by converting TH and LS-BMD measures to standardized BMD (sBMD) (22, 
23). All images were visually inspected for positioning errors (missing body mass coded 
none/unilateral/bilateral) and metal artefacts (coded none/rings/large jewellery or joint 
replacement). 
Assessment of osteoarthritis 
Radiographic  
Standing anteroposterior (AP), fully-extended, knee X-rays were performed at baseline and 
follow-up using standard protocols at each centre. To limit observer bias, all radiographs 
were pooled for analysis, with the reader blinded to HBM status, demographics and 
timepoint. Radiographs were graded for semi-quantitative OA sub-phenotypes 
(osteophytes/JSN, graded 0-3) and binary subchondral sclerosis using the OARSI atlas (24). 
Overall OA was graded using KL (25). The presence/absence of chondrocalcinosis was also 
assessed. Variables generated by KL grading and the OARSI atlas are summarised in Table 1, 
along with derived progression variables. Radiographs were inspected for poor image 
quality, rotation and/or tilt. Radiographs were viewed in open source imageJ software (26); 
minimal medial joint space width (mJSW) and maximum tibial plateau width were 




by one assessor (AH) after focussed radiological training with a musculoskeletal radiologist 
(MW) and a rheumatologist (SAH). A random selection of 72 knees (20%) were regraded to 
determine intra-rater reliability and graded by a second reader (SAH) to determine inter-
rater reliability. Weighted intra-rater kappa statistics for KL grade, all osteophyte and JSN 
variables, and unweighted kappa for chondrocalcinosis were >0.85. The intra-rater reliability 
kappa for subchondral sclerosis was 0.55, representing moderate agreement (27). Inter-
rater weighted kappas for KL grade and all osteophyte grades were >0.8. Medial and lateral 
JSN and chondrocalcinosis kappas were all >0.65. The inter-rater kappa for any subchondral 
sclerosis was 0.47. Intraclass correlation coefficients for intra- and inter-rater reliability of 
quantitative measures (mJSW, maximal tibial plateau width) were >0.99. 
Continuous measures of mJSW at the two timepoints were used to calculate a Reliable 
Change Index (RCI), which determines if the change in mJSW is meaningful over and above 
measurement error. Methodology for RCI calculation has been published elsewhere (28): 
 
The RCI is a Z-score and therefore a level exceeding 1.96 is used to denote a ‘true’ change 
over and above measurement error. A binary variable for reliable change in mJSW was 
therefore generated for those with an RCI<-1.96. 
Clinical 
Knee pain, stiffness and limitation of function were assessed by postal questionnaire at 8-
year follow-up. To limit non-response bias, the questionnaire was resent if not returned 
within three weeks. If still unreturned after a further two weeks, a reminder telephone call 
was made. The WOMAC questionnaire was included in this postal questionnaire; the short 
𝑅𝐶𝐼 =   
𝑚𝐽𝑆𝑊2 −  𝑚𝐽𝑆𝑊1
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version function scale was used to limit participant burden (29, 30). The pain subscale (five 
questions), stiffness (two questions) and function (seven questions), each had five possible 
responses (none, mild, moderate, severe, extreme) scored 0-4, respectively. Missing values 
for pain or function questions were mean-imputed if a participant was missing one question 
on the pain scale and <3 on the function scale. Average scores were calculated for each 
subscale and scaled to give a score ranging from 0-100, with 0 representing no pain, 
stiffness or limitation of function (31). Health-related quality of life (HR-QoL) was 
determined using the EuroQol EQ-5D questionnaire (32). Responses to the five questions 
were converted to index values using the crosswalk index value calculator and UK value set 
(33). If an individual was missing a response for any domain, an index value was not 
calculated.  
Covariate data 
At baseline, structured interview and clinical examination determined participant 
characteristics including age, menopausal status and standing height. Highest educational 
attainment (as a marker of socioeconomic status [SES]), determined by follow-up 
questionnaire, was categorised as up to GCSE/O-Level (or equivalent), A-Level (or 
equivalent) and degree level or above. Total body fat mass (TBFM) was assessed by TB DXA 
scans.  
Statistical analysis 
Associations between HBM status and binary OA incidence and progression variables were 
determined by multivariable poisson regression, to generate an estimate of the risk ratio 
(34), using generalized estimating equations (GEE) to account for clustering in knee 




variables were determined by multivariable GEE linear regression with robust standard 
errors to account for any non-normal distributions in outcome variables. Betas from analysis 
of continuous variables represent the difference in mean outcome between those with and 
without HBM (e.g. a beta of 1 for Δosteophyte represents a 1-point greater increase in 
summed osteophyte score). Osteophyte and/or JSN scores of 0 at baseline were included in 
analyses. Analyses were initially performed unadjusted (model 1), then adjusted for age and 
sex (and baseline sub-phenotype score for continuous outcomes) (model 2), then 
additionally adjusting for height, menopause and education (model 3). Our previous 
analyses have identified that HBM is associated with increased TBFM, with evidence 
suggesting this is a consequence rather than a cause of HBM (16). Therefore, adiposity is 
predicted to be on the causal pathway in these analyses, hence a possible mediating effect 
was determined by additional adjustment for TBFM in model 4. All analyses were restricted 
to individuals with complete data for model 4. Statistical analysis was performed in Stata 
version 15 (Statacorp, USA) and R version 3.5.1. In line with the recommendation of the 
American Statistical Association, we base our interpretation of the results on the size of 
associations and their confidence intervals (CIs), rather than p-values (35). 
Sensitivity analyses 
Joints with knee replacements (TKR) were excluded; however, as TKR were likely performed 
due to severe OA, analyses of progressive OA were repeated assuming knees with KL>2 and 
TKR at follow-up had progressive OA. Those with a baseline KL score<2 and TKR at follow-up 
were coded as both incident and progressive OA cases. A person-level analysis, using 
variables for OA progression in either knee or the highest value of the two knees for 




knees), knee lavage/washout/arthroscopy (16 knees) or a steroid injection (9 knees) by 
questionnaire were removed. A model adjusting for metal artefacts on DXA scans, and 
analyses removing individuals with positioning errors leading to under-measurement of 
TBFM by DXA (10 knees) were performed. We further adjusted for maximum tibial plateau 
width to determine whether BMD, rather than bone size, explained any associations 
observed. Finally, to check conclusions were valid despite skewed continuous outcomes, all 





Characteristics of the study population 
Baseline and follow-up radiographs were available from 169 individuals, 63% of whom had 
HBM. Mean follow-up time was 8.3 years (SD 1.0), which did not differ between individuals 
with and without HBM (Table 2). Those with follow-up data were more commonly female, 
premenopausal and physically active and less likely to smoke and have diabetes than 
individuals not followed-up, although the proportion of females in the baseline and follow-
up populations was similar (65 vs 73%, respectively) (Supplementary Table 1). No differential 
loss-to-follow-up between HBM cases and their relatives was evident; the baseline 
prevalence of kOA, kOA sub-phenotypes, and TKR were similar in those with and without 
follow-up radiographs.  
As expected, based on baseline observations, individuals with HBM were more commonly 
female (84% vs 55%), postmenopausal (74% vs 53%) with greater baseline BMD (mean TH-
BMD 1.25 vs 0.97g/cm2) and BMI (30.4 vs 27.7kg/m2) than individuals without HBM (Table 
2). Overall, changes in TH and LS-BMD over eight years were minimal; more marked declines 
in TH-BMD in HBM individuals (-0.44 vs -0.09% per year) were explained by older age of 
HBM cases in regression analyses.  
HBM and the incidence and progression of OA overall 
The prevalence of radiographic kOA (KL>2) was higher at both baseline and follow-up in 
individuals with HBM compared with those with normal BMD (34 vs 18% at baseline,50 vs 
27% at follow-up, Table 3). After adjustment (model 4) a weak trend was seen towards 




individuals, but confidence intervals (CIs) were wide. Combining incident and progressive OA 
as a single variable, we observed increased risk of incident/progressive OA in individuals 
with HBM (OR=1.76[1.03,3.02]).  
HBM and the incidence and progression of OA sub-phenotypes 
Individuals with HBM had greater osteophyte development (Δosteophyte: change in 
summed osteophyte score since baseline, reflecting incidence and/or progression) than 
individuals without HBM (unadjusted mean difference=0.65[0.22,1.08],p=0.003, Figure 1). 
Adjustment for age, sex, baseline osteophyte score, menopause, SES, height and TBFM 
explained approximately one-third of this relationship (fully-adjusted mean 
difference=0.44[0.02,0.87],p=0.041). Furthermore, a strong association between baseline 
TH-BMD and osteophyte development was observed (β=0.28[0.05,0.51],p=0.019, β 
represents the change in Δosteophyte score per SD increase in TH-BMD). No association 
between change in TH-BMD and osteophyte development was evident (Supplementary 
Figure 2).  
Development of JSN was more common in individuals with HBM, independent of TBFM, but 
this association (mean difference=0.16[0.02,0.29],p=0.028) was less pronounced than that 
seen for osteophyte development. When JSN development was measured using reliable 
change in mJSW, HBM individuals had an increased risk of ‘true’ JSN, independent of TBFM 
(RR=6.94[1.10,43.6],p=0.039), although CIs were wide reflecting the rarity of this outcome. 
Whilst baseline TH-BMD was associated with increased risk of reliable change in mJSW 
(fully-adjusted RR=2.59[1.29,5.19],p=0.007), change in TH-BMD between baseline and 




of chondrocalcinosis and subchondral sclerosis were similar in those with and without HBM 
(Supplementary Table 2), as was the incidence of both (Figure 1).  
HBM and clinical features of OA  
Before adjustment (model 1), individuals with HBM had approximately 10-point higher 
WOMAC scores (βpain=11.2[5.4,17.0], βstiffness=11.0[4.5,17.5] and βfunction=9.7[4.8,14.7], all 
p<0.001), compared to relatives with normal BMD. In analyses adjusted for age, sex, height, 
menopause and SES (model 3), these associations persisted with mean differences in 
WOMAC scores all >6.5/100 (Figure 2). Further adjustment for TBFM or JSN score 
attenuated these associations by approximately 20%, whereas adjustment for follow-up 
osteophyte score attenuated these associations by >50%. The same pattern was observed 
for HR-QoL, with HBM individuals having a lower HR-QoL compared to relatives without 
HBM (βmodel 3=-0.07[-0.13,-3.90x10-3]), with further adjustment for osteophyte scores 
attenuating this association by a greater proportion than TBFM or JSN adjustment (Figure 
2).  
Investigating dose-response relationships between BMD and OA outcomes 
Baseline TH-BMD Z-score was categorized into quartiles in both the HBM and non-HBM 
populations. Osteophyte development increased with increasing TH-BMD quartile in the 
HBM population (p for trend=0.043), until quartile 4, where mean Δosteophyte score 
appeared to plateau; no such relationship was seen in the non-HBM group (Figure 3A). No 
evidence of a dose-response relationship between TH-BMD and ΔJSN was detected (Figure 
3B). A clear dose-response relationship between TH-BMD and WOMAC pain scores was 






Findings were consistent when analyses were performed at a person-level, although CIs 
widened. Including ten additional knees with baseline OA and incident TKR strengthened 
the magnitude of the association between HBM and OA progression (fully-adjusted RR=1.99 
[0.87,4.54]), but CIs were still wide as only 86 individuals had OA at baseline (i.e. could 
progress). Including three knees, with KL<2 at baseline and TKR at follow-up, as incident OA 
weakened evidence for an association between HBM and incident OA (RR=1.53[0.82,2.87]). 
Excluding five individuals who attended a different study site for their follow-up radiographs 
did not alter findings, nor did adjustment for metal artefacts or removal of individuals with 
DXA positioning errors. Excluding knees of individuals self-reporting a prior cartilage 
operation or knee washout/lavage/arthroscopy marginally strengthened the association 
between HBM and Δosteophytes, but otherwise conclusions were unchanged 
(Supplementary Figure 3). Additional adjustment for maximum tibial plateau width did not 
attenuate the association between HBM and osteophyte development. Repeating analyses 





This study is the first to evaluate progression of sub-phenotypes of kOA in a population with 
HBM. Both initial appearance and subsequent growth of osteophytes are increased in 
individuals with HBM compared to those with normal BMD. Furthermore, we have shown 
that HBM individuals suffer a greater burden of clinical symptoms of kOA (pain, stiffness and 
functional limitation), with poorer HR-QoL, with symptoms largely explained by adjustment 
for osteophytosis severity. Our results are consistent with the one general population study 
which identified a positive relationship between LS-BMD and knee osteophyte progression 
(10). 
The relationship between high BMI and kOA is widely acknowledged (17, 36).HBM is 
characterised by increased TBFM (16), with development of HBM likely preceding fat mass 
accumulation due to its genetic origin (37).TBFM could mediate the association between 
HBM and OA progression through increased joint loading or other metabolic pathways. 
However, the associations we observed between HBM and greater osteophyte development 
were independent of TBFM. This finding is consistent with one earlier population-based 
study of North American women in whom those with low BMD and low BMI had the lowest 
KL grades, those with high BMD and high BMI had the highest KL grades, and those with low 
BMI and high BMD had similar KL grades to those with high BMI and low BMD, suggesting 
that the underlying biological pathway leading to increased osteophyte development in 
individuals with higher BMD is independent of adiposity (3).   
Our previous analyses of this HBM population identified an increased presence of 
enthesophytes, reflecting their ‘bone-forming’ phenotype (38). Increased osteophyte 




and kOA are highly heritable (39, 40), one potential explanation for this ‘bone-forming’ 
phenotype is pleiotropy, whereby the same genetic variants contribute to both phenotypes: 
genetic analyses in the Osteoarthritis Initiative and JoCo populations identified a positive 
association between four BMD-associated genetic single nucleotide polymorphisms (SNPs) 
and kOA (41).  Such pleiotropy could reflect a causal pathway between BMD and kOA, 
supported by a recent mendelian randomisation (MR) study (42), or shared underlying 
biological pathways contributing to both phenotypes. Individuals with HBM have an over-
representation of common BMD-associated variants, including those which annotate to 
bone-forming pathways, e.g.Wnt signalling (37), also linked to OA (43). Although, a more 
recent genome-wide analysis did not find evidence for a genetic correlation between FN-
BMD and kOA (44). Differences in subchondral bone texture may explain the positive, albeit 
weaker, association between HBM and JSN progression (1). Higher trabecular number and 
thickness plus reduced trabecular separation in subchondral bone have been linked to 
medial JSN progression (45). Individuals with HBM have increased trabecular density at both 
the tibia and radius (19); it is currently unknown whether HBM individuals have altered 
subchondral trabecular bone texture predictive of JSN progression. 
In contrast to our analysis, Zhang et al found that risk of kOA progression declined with 
increasing BMD in the Framingham cohort (6). One possible explanation for this disparity is 
that authors defined kOA progression as change in KL score in those with prevalent kOA at 
baseline. To have KL>2, an individual must present with osteophytes and to increase KL 
grade, JSN must occur (25). Therefore, progression from KL=2 to KL=3 relies solely on 
incident JSN, not worsening of osteophyte grade. Using an increased KL grade to define 
progression is also vulnerable to bias due to a ceiling effect, as those with a KL grade of 4 at 




association in the Framingham study is ‘collider bias’, as analyses were restricted to those 
with kOA at baseline (i.e. case only), thereby potentially inducing a negative correlation 
between BMD and any other variable that influences incident OA. If any such variable is also 
associated with progression and is not appropriately controlled for in the analysis, a 
‘backdoor pathway’ from high BMD to kOA progression can be induced.  This can manifest 
as a negative association, when in fact there is none, or even a true positive association (46).  
Our finding that individuals with HBM suffer increased clinical symptoms of OA, 
independent of TBFM, is consistent with a recent MR analysis which identified a causal 
relationship between FN-BMD and hospital-diagnosed kOA, even after excluding BMI-
associated SNPs from the instrument (42). OA is frequently diagnosed clinically due to 
symptoms, such as pain, rather than by radiography (47) and therefore hospital-diagnosed 
kOA is likely to reflect symptomatic OA, confirmed by radiographic changes. One Bradford-
Hill criterion supporting causal inference is a dose-response relationship (48); we found 
increased WOMAC pain scores with increasing TH-BMD quartiles in HBM individuals. The 
observation that adjustment for osteophyte severity at follow-up attenuated the association 
between HBM and pain to a greater extent than adjustment for JSN is consistent with the 
findings of Cicuttini et al, who observed that the odds of ever having knee pain was 
increased in middle-aged women with osteophytes compared to those without osteophytes, 
and this association was stronger than the association between knee JSN and knee pain 
(49). However, Neogi et al found that JSN, rather than osteophytes, was more strongly 
related to knee pain in individuals with knees discordant for pain (50). 




The HBM study constitutes a large cohort of individuals with relatively rare, unexplained, 
generalized HBM (14). Detailed data were collected at baseline and follow-up allowing for 
adjustment for potential confounders. We analysed change in OA sub-phenotypes 
separately as well as using KL score, which allowed us to detect the strong relationship with 
osteophyte development and the weaker relationship with change in JSN. We analysed 
change in osteophytes and JSN as continuous measures, increasing statistical power to 
detect associations, and reducing the possibility of a ceiling effect by increasing the range of 
possible values from 0-6 for JSN and 0-12 for osteophytes. However, this study has some 
limitations. The method of identifying individuals from NHS DXA databases ascertained an 
older population such that a relatively large proportion were unable to be followed-up due 
to death or poor health. X-rays and DXA scans were performed using standard protocols at 
each centre but were not cross-calibrated. Sample size restrictions meant we could not 
evaluate change in osteophyte score in individuals with osteophytes at baseline 
(progression) separately from those with no osteophytes at baseline (incidence).  A small 
number of individuals (0.3%) had a baseline summed osteophyte score of at least 10, almost 
the maximum score, meaning progression of summed score was limited. All those with a 
score >10 at baseline were HBM cases, meaning the relationship between HBM and 
osteophyte progression may have been underestimated due to a possible ceiling effect. 
Baseline and follow-up radiographs were not read paired and we did observe a few negative 
scores for change in osteophytes (<4%) and change in JSN (<2%), which were included in 
analyses. Removing these values as ‘measurement error’ could have biased results as there 
is likely to be the same proportion of measurement error overinflating change, for which we 
would not be able to account. Reassuringly, the small proportion with negative values did 




subjective, which we limited using an established atlas (24), and our intra-rater and inter-
rater reliability were substantial for all variables except subchondral sclerosis (27). WOMAC 
scores were only collected at follow-up and therefore we were not able to assess change in 
symptoms. Finally, as this is an extreme population with a female majority, generalizability is 
limited. 
Conclusions 
We have found evidence that individuals with HBM have increased osteophyte 
development over eight years, independent of fat mass, and a greater number and/or size 
of osteophytes is associated with greater pain, stiffness and functional limitation and 
reduced HR-QoL. Future analyses are planned to determine the underlying biological 
pathways leading to this increased osteophyte development. It is hoped that understanding 
of such pathways will offer opportunities to identify targets for therapies aimed at reducing 
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Table 1: Variables generated by Kellgren-Lawrence grading and the OARSI atlas and 
variables derived for analysis 
Variable Grading Variable used in analysis 
Osteoarthritis (KL grade) 0-4 Progressive OA: KL grade >2 at baseline and an increase in grade 
at follow-up 
Incident OA: KL grade <2 at baseline and >2 at follow-up 
   
Osteophytes Osteophyte progression: Sum of all semi-quantitative 
osteophyte grades at follow-up – sum at baseline  Medial femoral 0-3 
 Lateral femoral 0-3 
 Medial tibial 0-3 
 Lateral tibial 0-3 
    
JSN JSN progression: Sum of both semi-quantitative JSN grades at 
follow-up – sum at baseline  Medial 0-3 
 Lateral 0-3 
    
Subchondral sclerosis Incident sclerosis: no sclerosis (medial or lateral) at baseline and 
any sclerosis at follow-up  Medial 0, 1 
 Lateral 0, 1 
    
Chondrocalcinosis 0, 1 Incident chondrocalcinosis: no chondrocalcinosis at baseline and 
chondrocalcinosis at follow-up 
   
mJSW continuous Change in mJSW: mJSW at follow-up – mJSW at baseline 
Reliable change in mJSW: Reliable change index <-1.96 
Abbreviations: OARSI: osteoarthritis research society international; KL: Kellgren-Lawrence; JSN: joint 















p value for 
difference 
 N (%)  
Female gender 124 (73.3) 90 (84.1) 34 (54.8) 7.22x10-5 
 Postmenopausal at baseline 85 (68.5) 67 (74.4) 18 (52.9) 0.037 
 Menopause transition during follow-
up 
13 (10.8)a 7 (8.1) 6 (17.7) 0.131 
 History of ERT useb  55 (45.5)c 44 (50.0) 11 (33.3) 0.151 
History of smokingb  81 (50.6) 49 (49.0) 32 (53.3) 0.596 
Alcohol consumptionb     0.037 
 Never 15 (9.0) 7 (6.7) 8 (12.9)  
 Monthly or less 60 (35.9) 46 (43.8) 14 (22.6)  
 Weekly 49 (29.3) 29 (27.6) 20 (32.3)  
 Daily/ most days 43 (25.8) 23 (21.9) 20 (32.3)  
Physical activity at baseline    0.453 
     Low  19 (11.6)d 11 (10.8) 8 (12.9)  
     Medium  58 (35.4) 33 (32.4) 25 (40.3)  
     High 87 (53.0) 58 (56.9) 29 (46.8)  
Educatione    0.061 
     Up to GCSE/ O level 67 (41.4) 50 (48.1) 17 (29.3)  
     A level or equivalent 37 (22.8) 22 (21.2) 15 (25.9)  
     Degree or equivalent 58 (35.8) 32 (30.8) 26 (44.8)  
 Mean (SD)  
Age at baseline, years  57.7 (12.3) 58.4 (12.6) 56.4 (11.7) 0.303 
Age at follow-up, years 65.9 (12.4) 66.7 (12.7) 64.7 (11.8) 0.312 
Height at baseline, cm  167.7 (9.2) 166.5 (8.0) 169.8 (10.6) 0.036 
Weight at baseline, kg  82.6 (17.6) 84.1 (17.6) 80.0 (17.4) 0.146 
BMI at baseline (kg/m2) 29.4 (5.9) 30.4 (6.2) 27.7 (5.0) 0.003 
TBFM (kg)f 32.1 (10.9) 33.2 (11.3) 30.0 (10.0) 0.076 
Baseline TH Z-Score 2.03 (1.50) 2.96 (0.95) 0.46 (0.80) 8.55x10-39 
Baseline TH-BMD, g/cm2 g 1.15 (0.19) 1.25 (0.14) 0.97 (0.13) 1.03x10-26 
Change in TH-BMD, % per yearg -0.31 (0.92) -0.44 (0.94) -0.09 (0.84) 0.020 
Baseline L1 Z-Score 2.47 (1.96) 3.64 (1.25) 0.44 (1.14) 4.20x10-37 
Baseline L1-BMD, g/cm2 h 1.26 (0.22) 1.38 (0.15) 1.06 (0.14) 1.39x10-29 
Change in L1-BMD, % per yearh 0.02 (1.19) 0.02 (1.24) 0.02 (1.09) 0.994 
Follow-up time, years  8.3 (1.0) 8.3 (0.7) 8.2 (1.3) 0.871 
a: N=120 (86 HBM, 34 relatives); b: past or present (assessed at follow-up); c: N=112 (81 HBM, 31 
relatives) c: N=121 (88 HBM, 33 relatives); d: N=164 (102 HBM); e: N=162 (104 HBM, 58 relatives); f: 
assessed at follow-up; g: N=166 (104 HBM); h: N=167 (105 HBM) 
Abbreviations: ERT: estrogen replacement therapy; BMI: body mass index; TBFM: total body fat 





Table 3: Prevalence of radiographic and clinical OA sub-phenotypes in the study 
population 
 All knees HBM knees  Non-HBM knees  
 Total N N (%) Total N N (%) Total N N (%)  
OA (KL>2)        
 Baseline 330 94 (28.48) 209 72 (34.45) 121 22 (18.18) ** 
 Follow-up 312 129 (41.35) 194 97 (50.00) 118 32 (27.12) *** 
 Incident 232 55 (23.71) 135 41 (30.37) 97 14 (14.33) ** 
 Progressive 80 24 (30.00) 59 19 (32.20) 21 5 (23.81)  
Knee replacement        
 Baseline 337 7 (2.08) 214 5 (2.34) 123 2 (1.63)  
 Follow-up 337 25 (7.42) 214 20 (9.35) 123 5 (4.07)  
 Incident 330 18 (5.45) 209 15 (7.18) 121 3 (2.48)  
Subchondral sclerosis      
  Baseline 330 6 (1.82) 209 4 (1.91) 121 2 (1.65)  
 Follow-up 312 19 (6.09) 194 11 (5.67) 118 8 (6.78)  
 Incident 310 17 (5.48) 193 10 (5.18) 117 7 (5.98)  
Chondrocalcinosis        
 Baseline  330 18 (5.45) 209 11 (5.26) 121 7 (5.79)  
 Follow-up  312 39 (12.50) 194 26 (13.40) 118 13 (11.02)  
 Incident  297 26 (8.75) 186 20 (10.75) 111 6 (5.41)  
Reliable change in mJSW 
(RCI<-1.96) 
299 16 (5.4) 189 14 (7.41) 110 2 (1.82) * 
Osteophyte score        
 Baseline 330  209  121  ** 
      0  236 (71.52)  137 (65.55)  99 (81.82)  
      1-4  79 (23.94)  59 (28.23)  20 (16.53)  
      >5  15 (4.55)  13 (6.22)  2 (1.65)  
 Follow-up 312  194  118  *** 
      0  183 (58.65)  97 (50.00)  86 (72.88)  
      1-4  97 (31.09)  69 (35.57)  28 (23.73)  
      >5  32 (10.26)  28 (14.43)  4 (3.39)  
 Delta 312  194  118   *** 
      <1  211 (67.63)  115 (59.28)  96 (81.36)  
      1  33 (10.58)  25 (12.89)  8 (6.78)  
      >1  68 (21.79)  54 (27.84)  14 (11.86)  
JSN score        
 Baseline 330  209  121   
      0  283 (85.76)  177 (84.69)  106 (87.60)  
      1-2  43 (13.03)  29 (13.88)  14 (11.57)  
      >3  4 (1.21)  3 (1.44)  1 (0.83)  
 Follow-up 312  194  118   
      0  244 (78.21)  146 (75.26)  98 (83.05)  
      1-2  59 (18.91)  40 (20.62)  19 (16.10)  
      >3  9 (2.88)  8 (4.12)  1 (0.85)  
 Delta 312  194  118  * 
      <1  267 (85.58)  162 (83.51)  105 (88.98)  
      1  35 (11.22)  22 (11.34)  13 (11.02)  
      >1  10 (3.21)  10 (5.15)  0 (0.00)  
 Total N Median (IQR)  Total N Median (IQR)  Total N Median (IQR)  
        
         





*: p<0.05; **:p<0.01, ***:p<0.001 
a: P values for skewed outcomes were generated from a Mann-Witney U test. 
Abbreviations: HBM: high bone mass; KL: Kellgren-Lawrence; JSN: joint space narrowing; RCI: reliable 
change index; mJSW: medial minimal joint space width 
         
        
         
         
         
WOMAC at follow-up       
 Pain 154 5 (0, 30) 100 12.5 (0, 40) 54 0 (0, 10) ***a 
 Stiffness 153 12.5 (0, 37.5) 99 25 (0, 50) 54 0 (0, 25) **a 
 Function 153 3.6 (0, 28.6) 99 10.7 (0, 39.3) 54 0 (0, 17.9) **a 
  Total N Mean (SD) Total N Mean (SD) Total N Mean (SD)  
mJSW        
 Baseline 328 4.98 (1.17) 209 5.02 (1.18) 119 4.92 (1.14)  
 Follow-up 300 4.84 (1.39) 188 4.89 (1.53) 112 4.76 (1.11)  





Figure 1: Associations between HBM status and incident and progressive OA sub-
phenotypes 
Points for continuous outcomes represent the difference in mean outcome between individuals with 
and without HBM (For example, a beta of for Δosteophyte would represent a 1 point greater 
increase in summed osteophyte score, which is the equivalent of the appearance of one additional 
osteophyte over 8 years or the increase in size of an osteophyte already present). Points for binary 
outcomes represent the risk ratio for individuals with HBM compared to their relatives with normal 
BMD  
Model 1: unadjusted, Model 2: adjusted for age and sex (plus baseline score for continuous 
outcomes), Model 3: adjusted for age, sex, height, SES and menopause (plus baseline score for 
continuous outcomes), Model 4: Model 3 plus TBFM 
NmJSW=278; Nchondrocalcinosis=274; Nsubchondral sclerosis=287. Abbreviations: JSN: joint space narrowing; 
mJSW: medial minimal joint space width 
Figure 2: Associations between HBM status and WOMAC pain, stiffness and function 
subscale scores and health-related quality of life 
Points represent the mean difference in WOMAC scores between individuals with HBM and 
relatives/ spouses without HBM. Person-level analysis, accounting for clustering in families. Follow-
up osteophyte and JSN score is the highest of the two knees. Model 1: unadjusted, Model 3: 
adjusted for age, sex, height, SES and menopause.  Nstiffness/function=148 
Figure 3: Association between quartiles of total hip BMD Z-score and (A) change in 
osteophyte score, (B) change in JSN score and (C) WOMAC pain scores in individuals with 




Results for mean osteophyte scores are based on GEE-linear regression accounting for two knees per 
individual. 
Abbreviations: TH-BMD: total hip bone mineral density 
